Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Ropinirole is marketed in Australia as Appese, Haruropi and Repreve.
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
Select your state to see jurisdictional framework, reporting obligations, and authority links. Substance information above is the same in every state.
“Ropinirole hydrochloride is a non-ergot dopamine agonist created based on the structure of dopamine, and exhibits antiparkinsonian effects by stimulating dopamine D 2 like receptors.”
“Consistent with its high lipophilicity, ropinirole exhibits a large volume of distribution (approximately 7 L/kg) and is cleared from the systemic circulation with an average elimination half-life of about 10 hours after transdermal administration.”
A plain-language summary of the cited sources below. Informational only — not medical advice.
Clinical Summary for Prescribers: Ropinirole (S4)
Ropinirole is a non-ergot dopamine agonist in the dopamine agonists class, listed as Schedule S4, indicated for idiopathic Parkinson’s disease from early stage to advanced disease.
Mechanism: Ropinirole acts as a D2, D3, and D4 dopamine receptor agonist, with highest affinity for D3 receptors, which are predominantly in limbic areas. It is weakly active at 5-HT2 and α
Ropinirole is marketed in Australia as Appese, Haruropi and Repreve.
3 brand names are recorded against this substance from the TGA eBS Product Information repository. The full list is in the Also known as card.
“Ropinirole is mainly metabolized to the depropylated form in the liver. CYP1A2 has been reported to be involved in the ropinirole metabolite in vitro. Ropinirole hydrochloride is primarily cleared by CYP1A2 metabolism and its metabolites are mainly excreted in urine.”